ROS-sensitive dihydroartemisinin prodrug amplify chemo-immunotherapy efficacy of doxorubicin by coordinating robust tumor cell immunogenic cell death and PD-L1 blockade
aDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China
bDepartment of Industrial and Molecular Pharmaceutics, Purdue University, West Lafayette, IN 47907, United States
cKey Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, China; State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, China
dSchool of Pharmacy, Fujian Medical University, Fuzhou 350122, China
eFujian Key Laboratory of Natural Medicine Pharmacology, School of Pharmacy, Fujian Medical University, Fuzhou 350122, China
收起